Adults aged 18 to 75 years old diagnosed with plaque psoriasis for at least 6 months, may qualify to participate. Individuals must have moderate to severe plaque psoriasis involving 10% or more body surface area (BSA). Avoidance of any prolonged exposure to natural or artificial sources of ultraviolet (UV) radiation (e.g. sunlight, tanning beds or phototherapy) is also required.
Participants will receive investigational medication (active study drug) or placebo in tablet formulation. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.
Study participation will last about 21 weeks and involve about 7 visits to the study centre.